Related Experiment Video
Updated: Aug 17, 2025

Establishment and Characterization of UTI and CAUTI in a Mouse Model
Published on: June 23, 2015
Sodium-Glucose Cotransporter 2 Inhibitors and Urinary Tract Infection: Is There Room for Real Concern?
Nasim Wiegley1, Paolo Nikolai So2
1Division of Nephrology, School of Medicine, University of California, Davis, Sacramento, California.
Abstract:
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have revolutionized our armamentarium for kidney and heart protection in patients with or without diabetes. Based on early reports of a limited number of cases, a concern for increased risk of urinary tract infections arose, which has become one of the main areas of concern for some clinicians. However, data from large randomized clinical trials and real-world population-based studies have not shown a significantly increased risk of UTI in patients on SGLT2 inhibitors. The goal of this brief review article is to review the literature and provide reassurance to patients and prescribers for the broader use of these agents.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Secondary Active Transport
Urinary Tract Infection II: Pathophysiology
Urine Studies II: Urine Culture and Sensitivity Test
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucose Absorption Into the Small Intestine

